Involvement of p53 in cell differentiation and development

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1333, Issue 1, 1997, Pages

  Almog, Nava ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CELL DIFFERENTIATION; DNA DAMAGE; EMBRYO DEVELOPMENT; GENE INDUCTION; GENE REARRANGEMENT; GENE TARGETING; GROWTH REGULATION; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPERMATOGENESIS; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; DNA DAMAGE; EMBRYONIC AND FETAL DEVELOPMENT; GENE REARRANGEMENT; GENE THERAPY; GENES, P53; GROWTH; HUMANS; IMMUNE SYSTEM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030791113     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-419X(97)00012-7     Document Type: Review

References (203)

1. Linzer D.I.H., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 17:1979;43-52.
2. Lane D., Crawford L. T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:1979;261-263.
3. Rotter V., Boss M.A., Baltimore D. Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents. J Virol. 38:1981;336.
4. Rotter V. p53, a transformation-related cellular encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc. Natl. Acad. Sci. USA. 80:1983;2613-2617.
5. Harris C.C. The 1995 Walter Hubert Lecture-Molecular Epidemiology of Human Cancer: Insights from the mutational analysis of p53 Tumor Suppressor Gene. Br. J. Cancer. 73:1996;261-269.
6. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: A second look. J. Mol. Biol. 260:1996;623-637.
7. Ko J.L., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
8. Mercer W.E., Shields M.T., Amin M., Sauve G.J., Appella E., Romano J.W., Ullrich S.J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild type p53. Proc. Natl. Acad. Sci. USA. 87:1990;6166-6170.
9. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:1990;671-680.
10. Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:1990;5772-5781.
11. Shaulsky G., Goldfinger N., Peled A., Rotter V. Involvement of wild type p53 in pre-B cell differentiation in vitro. Proc. Natl. Acad. Sci. USA. 88:1991;8982-8986.
12. Ryan J.J., Danish R., Gottlieb C.A., Clarke M.F. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol. Cell. Biol. 13:1993;711-719.
13. Yin Y., Tainsky M.A., Bischoff F.Z., Strong L.C., Wahl G.M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 70:1992;937-948.
14. 1 arrest. Cell. 76:1994;1013-1023.
15. Yonish-Rouach E., Resnitzky K., Lotem J., Sachs L., Kimchi A., Oren M. Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature. 352:1991;345-347.
16. Yonish-Rouach E., Grunwald D., Wilder S., Kimchi A., May E., Lawrence J.J., May P., Oren M. p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol. 13:1993;1415-1423.
17. Oren M. Relationship of p53 to the control of apoptotic cell death. Sem. Canc. Biol. 5:1994;221-227.
18. 2-dependent immunoglobulin κ light chain gene expression. EMBO J. 14:1995;1392-1401.
19. Ronen D., Schwartz D., Teitz Y., Goldfinger N., Rotter V. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild type p53 protein whereas their differentiation is mediated by lower p53 levels. Cell Growth Diff. 7:1996;21-30.
20. Rotter V., Aloni-Grinstein R., Schwartz D., Elkind N.B., Simons A., Wolkowicz R., Lavigne M., Besserman P., Kapon A., Goldfinger N. Does wild type p53 play a role in normal cell differentiation? Sem. Cancer Biol. 5:1994;229-236.
21. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
22. Kuerbitz S.J., Plunkett B.S., Walsh W.V., Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:1992;7491-7495.
23. Lu X., Lane D.P. Differential induction of transcriptionally active p53 following UV or ionizing irradiation: Defects in chromosome instability syndromes? Cell. 75:1993;765-778.
24. Nelson W.G., Kastan M.B. DNA strand breaks-the DNA template alteration that triggers p53 dependent DNA damage response pathways. Mol. Cell. Biol. 14:1994;1815-1823.
25. Cross S.M., Sanchez C.A., Morgan C.A., Schimke M.K., Ramel S., Idzerda R.L., Raskind W.H., Reid B.J. A p53-dependent mouse spindle checkpoint. Science. 267:1995;1353-1356.
26. Wells W.A.E. The spindle-assembly checkpoint: aiming for a perfect mitosis, every time. Trends Cell Biol. 6:1996;228-234.
27. Lane D.P. p53, guardian of the genome. Nature. 358:1992;15-16.
28. Maltzman W., Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1984;1689-1694.
29. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunket B.S., Vogelstein B., Fornace A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telangiectasia. Cell. 71:1992;587-597.
30. Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70:1992;923-935.
31. Lee S., Elenbaas B., Levine A., Griffith J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell. 81:1995;1013-1020.
32. Sanchez Y., Elledge J.S. Stopped for repairs. BioAssays. 17:1995;545-548.
33. Smith M.L., Chen I.-T., Zhan Q., Bae I., Chen C.-Y., Glimer T.M., Kastan M.B., O'Connor P.M., Fornace J.A.J. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 266:1994;1376-1378.
34. Shivakumar V.C., Brown R.D., Deb S., Palit Deb S. Wild type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol. Cell. Biol. 15:1995;6785-6793.
35. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J., Harris C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA. 91:1994;2230-2234.
36. Ford J.M., Hanawalt P.C. Li-Fraumeni Syndrome Fibroblasts Homozygous for p53 Mutations are Deficient in Global DNA Repair but Exhibit Normal Transcription-Coupled Repair and Enhanced UV-Resistance. Proc. Nat. Acad. of Sci. USA. 92:1995;8876-8890.
37. Dutta A., Ruppert J.M., Aster J.C., Wincherester E. Inhibition of DNA replication factor RPA by p53. Nature. 365:1993;79-82.
38. Wang X.W., Yeh H., Schaeffer L., Roy R., Moncolli V., Egly J.-M., Wang Z., Friedberg E.C., Evans M.K., Taffe B.G., Bohr V.A., Weeda G., Hoeijmakers J.H.J., Forrester K., Harris C.C. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet. 10:1995;188-195.
39. Harvey M., Sands T.A., Weiss S.R., Hegi E.M., Wiseman W.R., Pantazis P., Giovanella C.B., Tainsky A.M., Bradley A., Donehower A.L. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene. 8:1993;2457-2467.
40. Fukasawa K., Choi T., Kuriyama R., Rulong S., Vande Woude G.F. Abnormal centrosome amplification in the absence of p53. Science. 271:1996;1744-1747.
41. Peled A., Schwartz D., Elkind N.B., Wolkowicz R., Li R., Rotter V. The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells. Oncogene. 13:1996;1677-1685.
42. Jacobson D.M., Weil M., Raff C.M. Programmed cell death in animal development. Cell. 88:1997;347-354.
43. Donehower L.A., Harvey M., Slagle B.T., McArthur M.J., Montgomery C.A., Butel J.S., Bradly A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 356:1992;215-221.
44. Shen D.-U., Real F.X., DeLeo A.B., Old L.J., Marks P.A., Rifkind R.A. Protein p53 and inducer-mediated erythroleukemia cell commitment to terminal cell division. Proc. Natl. Acad. Sci. USA. 80:1983;5919-5922.
45. Ben-Dori R., Renitzki D., Kimchi A. Reduction in p53 synthesis during differentiation of Friend-erythroleukemia cells. Correlation with the commitment to terminal cell division. FEBS Lett. 162:1983;384-388.
46. Richon M.V., Ramsay G.R., Rifkind A.R., Marks A.P. Modulation of the c-myb, c-myc and p53 mRNA and protien levels during induced murine erythroleukemia cell differentiation. Oncogene. 4:1989;165-173.
47. Khochbin S., Principaud E., Chabanas A., Lawrence J.-J. Early events in murine erythroleukemia cells induced to differentiate. Accumulation and gene expression of the transformation-associated cellular protein p53. J. Mol. Biol. 200:1988;55-64.
48. Finlay C.A., Hinds P.W., Levine A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 57:1989;1083-1093.
49. Eliyahu D., Michalovitz D., Eliyahu S., Pinhasi-Kimhi O., Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA. 86:1989;8763-8767.
50. Lane D.P., Benchimol S. p53: oncogene or anti-oncogene? Genes Dev. 4:1990;1-8.
51. Levine A.J. Tumor suppressor genes. BioAssays. 12:1990;60-66.
52. Mercer W.E., Shields M.T., Lin D., Appella E., Ullrich S.J. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA. 88:1991;1958-1962.
53. Nigro J.M., Baker J.S., Preisinger A.C., Jessup J.M., Hostetter K., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:1989;705-708.
54. Shaulsky G.N.G., Peled A., Rotter V. Involvement of Wild Type p53 Protein in the Cell Cycle Requires Nuclear Localization. Cell Growth Diff. 2:1991;661-667.
55. Wolf D., Rotter V. Major deletions in the gene encoding the p53 antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad. Sci. USA. 82:1985;790-794.
56. Vogelstein B. A deadly inheritance. Nature. 348:1990;681-682.
57. Rotter V., Witte O.N., Coffman R., Baltimore D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, p53. J. Virol. 36:1980;547-555.
58. Wolf D., Rotter V. Inactivation of p53 expression by an insertion of Moloney murine leukemia viral-like DNA sequences. Mol. Cell. Biol. 4:1984;1402-1410.
59. Rotter, V., Shaulsky, G. and Goldfinger, N. (1992) 43 237-257.
60. Shaulsky G., Goldfinger N., Rotter V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res. 51:1991;5232-5237.
61. Aloni-Grinstein R., Zan-Bar I., Alboum I., Goldfinger N., Rotter V. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene. 8:1993;3297-3305.
62. Kastan M.B., Radin A.I., Kuerbitz S.J., Onyekwere O., Wolkow C.A., Civin C.I., Stone K.D., Woo T., Ravindranath Y., Craig R.W. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res. 51:1991;4279-4286.
63. Soddu S., Blandino G., Citro G., Scardigli R., Piaggio G., Ferber A., Calabretta B., Sacchi A. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood. 83:1994;2230-2237.
64. Banerjee D., Lenz H., Schnieders B., Manno J.D., Ju F.J., Spears C.P., Hochhauser D., Danenberg K., Danenberg P., Bertino R.J. Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Diff. 6:1995;1405-1413.
65. Ehinger M., Bergh G., Olofsson T., Baldetorp B., Olsson I., Gullberg U. Expression of the p53 tumor suppressor gene induces differentiation and promots induction of differentiation by 1,25-Dihydroxycholecalciferol in leukemic U-937 cells. Blood. 3:1996;1064-1074.
66. Feinstein E., Gale P.B., Reed J., Cannai E. Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene. 7:1992;1853-1857.
67. Ehinger M., Nilsson E., Persson A., Olsson I., Gullberg U. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562. Cell Growth Diff. 6:1995;9-17.
68. Soddu S., Blandino G., Scardigli R., Coen S., Marchetti A., Rizzo M.G., Bossi G., Cimino L., Crescenzi M., Sacchi A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J. Cell Biol. 134:1996;1-12.
69. Johnson P., Chung S., Benchimol S. Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobulin production and is sensitive to erythropoitin. Mol. Cell. Biol. 13:1993;1456-1463.
70. Khochbin S., Brocard M.P., Grunwald D., Lawrence J.J. Antisense RNA and p53 regulation in induced murine cell differentiation. Ann. NY Acad. Sci. 660:1992;77-87.
71. Prokocimer M., Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood. 84:1994;2391-2411.
72. Halevy O. p53 gene is up-regulated during skeletal muscle cell differentiation. Biochem. Biophy. Res. Comm. 192:1993;714-719.
73. Radinsky R., Fidler J.I., Price E.J., Esumi N., Tsan R., Petty M.C., Bucana D.C., Bar-eli M. Terminal differentiation and apoptosis in lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene. 9:1994;1877-1883.
74. Weinberg C.W., Azzoli G.C., Chapman K., Levine J.A., Yuspa H.S. p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene. 10:1995;2271-2279.
75. Woodworth C.D., Wang H., Simpson S., Alvarez-Salas L.M., Notario V. Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth Diff. 4:1993;367-376.
76. 1. Cell Growth Diff. 4:1993;993-1004.
77. Spandau D.F. Distinct conformations of p53 are observed in different stages of keratinocyte differentiation. Oncogene. 9:1994;1861-1868.
78. A.P. Rehberger, K.H. Richter, D. Schwartz, N. Goldfinger, R. Oskato, N. Almog, F. Marks and V. Rotter, Differential expression of the regularly spliced p53 and the C-terminal alternatively spliced form in epidermal differentiation, 1997, submitted.
79. Keren-Tal I., Suh B., Dantes A., Linder S., Oren M., Amsterdam A. Involvement of p53 expression in cAMP-mediated apoptosis in immortalized granulosa cells. Exp. Cell Res. 218:1995;283-295.
80. Amsterdam A., Keren-Tal I., Aharoni D. ross-talk between cAMP and p53-generated signals in induction of differentiation and apoptosis in steroidogenic granulosa cells. Steroids. 61:1996;252-256.
81. Eizenberg O., Faber-Elman A., Gottlieb E., Oren M., Rotter V., Schwartz M. p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol. Cell. Biol. 16:1996;5178-5185.
82. Oren M., Reich N.C., Levine A.J. Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol. Cell. Biol. 2:1982;443-449.
83. Levine A.J., Oren M., Reich N., Sarnow P. The mechanisms regulating the levels of the cellular p53 tumor antigen in transformed cells. Adv. Viral Onc. 2:1982;81-102.
84. Reich N.C., Oren M., Levine A.J. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol. 3:1983;2143-2150.
85. Dony C., Kessel M., Gruss P. Post-transcriptional control of myc and p53 expression during differentiation of the embryonal carcinoma cell line F9. Nature. 317:1985;636-639.
86. Chandrasekaran K., Mora P.T., Nagarajan L., Anderson W.B. The amount of a specific cellular protein (p53) is a correlate of fifferentiation in embryonal carcinoma cells. J. Cell. Phys. 113:1982;134-140.
87. Kosaka M., Iwai A.S., Nishina Y., Sumi T., Nishimune Y. c-myc and p53 gene expression in the differentiation of temperature-sensitive mutants of teratocarcinoma F9 cells. Oncogene. 7:1992;2455-2460.
88. Lutzker S.G., Levine A.J. A functionally inactive p53 protein in teratocacinoma cells is activated by either DNA damage or cellular differentiation. Nature Med. 2:1996;804-810.
89. Fagin J.A., Tang S.-H., Zeki K., Di Lauro R., Fusco A., Gonsky R. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Canc. Res. 56:1996;765-771.
90. F. Moretti, A. Farsetti, S. Soddu, S. Misiti, S. Filetti, M. Andreoli, A. Sacchi and A. Pontecorvi, p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells, 1997.
91. Battista S., Martelli L.M., Fedele M., Chiappetta G., Trapasso F., De vitta G., Battaglia C., Santoro M., Viglietto G., Fagin A.J., Fusco A. A mutant p53 gene alters thyroid cell differentiation. Oncogene. 11:1995;2029-2037.
92. Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi T., Hayashi Y., Dohi K., Nakamura N., Akiyama M. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Canc. Res. 52:1992;1369-1371.
93. R. Donghi, A. Longoni, S. Pilotti, G. Della Porta and M.A. Pierotti, Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. 91, 1993, 1753-1760.
94. Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.-H., Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 91:1993;179-184.
95. Fagin J.A. Tumor supresor genes in human thyroid neoplasma: p53 mutations are associated with undifferentiated thyroid cancers. J. Endocrinol. Invest. 18:1995;140-142.
96. Pollina L., Pacini F., Fontanini G., Vignati S., Bevilacqua G., Basolo F. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br. J. Cancer. 73:1996;139-143.
97. Germani A., Fusco C., Martinotti S., Musaro A., Molinaro M., Zani M. TPA-induced differentiation of human rhabdomyosarcoma cells involves dephosphorylation anf nuclear accumulation of mutant p53. Biochem. Biophy. Res. Comm. 202:1994;17-24.
98. R. Wolkowicz and V. Rotter, The DNA binding regulatory domain of p53: see the C. Patologie-Biologie, 1997, in press.
99. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Activation of the cryptic DNA binding function of mutant forms of p53. Nucl. Acids Res. 21:1993;3167-3174.
100. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-886.
101. Wu Y., Liu Y., Lee L., Miner Z., Kulesz-Martin M. Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J. 13:1994;4823-4830.
102. Wolkowicz R., Peled A., Elkind N.B., Rotter V. The augmented DNA binding activity of an alternative spliced C′-terminal p53 is blocked by regular spliced p53 protein. Proc. Natl. Acad. Science USA. 92:1995;6842-6846.
103. Bayle J.H., Elenbaas B., Levine A.J. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl. Acad. Sci. USA. 92:1995;5729-5733.
104. Shohat-Foord O., Bhattacharya P., Reich Z., Rotter V. A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucl. Acids Res. 19:1991;5191-5198.
105. Wu L., Bayle H., Elenbaas B., Pavletich N.P., Levine A.J. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ablity to promoter annealing of complementary single strands of nucleic acids. Mol. Cell Biol. 15:1995;497-504.
106. Wang X.W., Vermwulen W., Coursen J.D., Gibson M., Lupold S.E., Forrester K., Xu G., Elmore L., Yeh H., Hoeijmakers J.H.J., Harris C.C. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Gene Dev. 10:1996;1219-1232.
107. Jayaraman L., Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell. 81:1995;1021-1029.
108. Reed M., Woelker B., Wang P., Wang Y., Anderson M.E., Tegtmeyer P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA. 92:1995;9455-9459.
109. Leveillard T., Andera L., Bissonnette N., Schaeffer L., Bracco L., Egly J., Wasylyk B. Functional interactions between p53 and the THIIH complex are affected by tumour-associated mutations. EMBO J. 15:1996;1615-1624.
110. Meek D.W., Simon S., Kikkawa U., Eckhart W. The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J. 9:1990;3253-3260.
111. Shaulsky G., Goldfinger N., Ben-Ze'ev A., Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell Biol. 10:1990;6565-6577.
112. Wolf D., Harris N., Goldfinger N., Rotter V. Isolation of full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol. Cell Biol. 5:1985;127-132.
113. Arai N., Nomura D., Yokota K., Wolf D., Brill E., Shohat O., Rotter V. Immunologically distinct p53 molecules generated by alternative splicing. Mol. Cell Biol. 6:1986;3232-3239.
114. Han K., Kulesz-Martin M.F. Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. Nucleic Acids Res. 20:1992;1979-1981.
115. Kulesz-Martin M.F., Lisafeld B., Huang H., Kisiel N.D., Lee L. Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell Biol. 14:1994;1698-1708.
116. Almog, N., Peled, A., Li, R., Schwartz, D., Wolkowicz, R., Goldfinger, N., Huiping, P. and Rotter, V. (1997) The murine C-terminal alternatively spliced p53 form induced an attenuated apoptosis in myeloid cells. Mol. Cel. Biol. 17.
117. Sjoblom T., Lahdetie J. Expression of p53 in normal and gamma-irradiated rat testis suggests a role for p53 in meiotic recombination and repair. Oncogene. 12:1996;2499-2505.
118. Mora P.T., Chandrasekaran K., McFarland V.W. An embryo protein induced by SV40 virus transformation of mouse cells. Nature. 288:1980;722-724.
119. Chandrasekaran K., McFarland V.W., Simmons D.T., Dziadek M., Gurney E.G., Mora P.T. Quantitation and characterization of a species-specific and embryo stage-dependent 55-kilodalton phosphoprotein also present in cells transformed by simian virus 40. Proc. Natl. Acad. Sci. USA. 78:1981;6953-6957.
120. Rogel A., Poplinker M., Webb S.G., Oren M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos and tumors. Mol. Cel. Biol. 5:1985;2851-2855.
121. Louis J.M., McFarland V.W., May P., Mora P.T. The phosphoprotein p53 is down-regulated post-transcriptionally during embryogenesis in vertebrates. Biochim. Biophysic. 950:1988;395-402.
122. Schmid P., Lorenz A., Hameister H., Montenarh M. Expression of p53 during mouse embryogenesis. Development. 113:1991;857-865.
123. Gottlieb, E., Haffner, R., King, A., Asher, G., Gruss, P., Lonai, P. and Oren, M. (in press) Transgenic mouse model for studying the transcriptional activity of the p53 protein: age and tissue dependent changes in radiation-induced activation during embryogenesis. EMBO.
124. Harvey M., McArthur J.M., Montgomery A.C.J., Bradley A., Donehower A.L. Genetic backround alters the specrtum of tumors that develop in p53-deficient mice. FASEB J. 7:1993;938-943.
125. Jacks T., Remington L., Williams O.B., Schmitt M.E., Halachmi S., Bronson T.R., Weinberg A.R. Tumor spectrum analysis in p53-mutant mice. Current biology. 4:1994;1-7.
126. Purdie A.C., Harrison J.D., Peter A., Dobbie L., White S., Howie M.E.S., Salter M.D., Bird C.C., Wyllie H.A., Hooper L.M., Clarke R.A. Tumor incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene. 9:1994;603-609.
127. Berns A. Is p53 the only real tumor suppressor gene? Current Biology. 4:1994;137-139.
128. Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant allels of the p53 oncogene. Mol. Cell Biol. 9:1989;3982-3991.
129. Sah V.P., Attardi L.D., Mulligan G.J., Williams B.O., Bronson R.T., Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat. Genetics. 10:1995;175-180.
130. Armstrong J.F., Kaufman M.H., Harrison D.J., Clarke A.R. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5:1995;931-936.
131. Nicol C.J., Harrison M.L., Laposa R.R.I.L.G., Wells P.G. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nat. Genetics. 10:1995;181-186.
132. Godley L.A., Kopp J.B., Eckhaus M., Paglino J.J., Varmus H.E. Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and posses small kidneys. Genes Dev. 10:1996;836-850.
133. Nakamura T., Pichel J.G., Williamssimons L., Westphal H. An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele. Proc Natl Acad Sci USA. 92:1995;6142-6146.
134. Morgenbesser S.D., Williams B.O., Jacks T., Depinho R.A. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 371:1994;72-74.
135. Griep E.A., Herber R., Jeon S., Lohse K.J., Dubielzig R.R., Lambert F.P. Tumorigennicity by human papillomavirus type 16 E6 and E7 in transgenic mice correlates with alternations in epithelial cell growth and differentiation. J. Virol. 67:1993;1373-1384.
136. Pan H., Griep E.A. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgemnic mice: Implications for tumor suppressor gene function in development. Genes Dev. 8:1994;1285-1299.
137. Pan H., Griep A.E. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev. 9:1995;2157-2169.
138. de Oca Luna R.M., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 378:1995;203-206.
139. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in mdm-2 deficient mice by absence of p53. Nature. 378:1995;206-208.
140. Almon E., Goldfinger N., Kapon A., Schwartz D., Levine A.J., Rotter V. Testicular tissue-specific expression of the p53 suppressor gene. Dev. Biol. 156:1993;107-116.
141. Schwartz D., Goldfinger N., Rotter V. Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene. 8:1993;1487-1494.
142. Rotter V., Schwartz D., Almon E., Goldfinger N., Kapon A., Meshorer A., Donehower L.A., Levine A.J. Mice with reduced levels of p53 exhibit the testicular giant cell degenerative syndrome. Proc. Natl. Acad. Sci. USA. 90:1993;9075-9079.
143. Bouck N. p53 and angiogenesis. BBA. 1287:1996;63-66.
144. Mukhopadhyay D., Tsiokas L., Sukhate me V.P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55:1995;6161-6165.
145. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1994;1582-1584.
146. Bourdon C.J., Deguin-hambon V., Lelong C.J., Dessen P., May P., Debuire B., May E. Further characterisation of the p53 responsive elemen - identification of new candidate genes for trans-activation by p53. Oncogene. 14:1997;85-94.
147. Van Meir E.G., Polverini P.J., Chazin V.R., Huang H.-J., de Tribolet N., Cavenee W.K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genetics. 8:1994;171-176.
148. Hawley R.S., Friend S.H. Strange bedfellows in even stranger places: the role of ATM in meiotic cells, lymphocytes, tumors, and its functional links to p53. Genes Dev. 10:1996;2382-2388.
149. Khanna K.K., Beamish H., Yan J., Hobson K., Williams R., Dunn I., Lavin F.M. Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia. Oncogene. 11:1995;609-618.
150. Artuso M., Esteve A., Bresil H., Vuillaume M., Hall J. The role of the ataxia telangiectasia gene in the p53, WAF/CIP/p21 and GADD45-mediated response to DNA damage produced by ionising radiation. Oncogene. 11:1995;1427-1435.
151. Meyn M.S. Ataxia-telangiectasia and cellular response to DNA damage. Cancer Res. 55:1995;5991-6001.
152. Jorgensen J.T., Shiloh Y. The ATM gene and the radiobiology of ataxia-telangiectasia. Int.J. Radiat. Biol. 69:1996;527-537.
153. Xu Y., Ashley T., Brainerd E.E., Bronson R.T., Meyn M.S., Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10:1996;2411-2422.
154. Jackson P.S., Jeggo A.P. DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. TIBS. 20:1995;412-415.
155. Bogue M.A., Zhu C., Aguilar-Cordova E., Donehower L.A., Roth D.B. p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in scid mouse thymocytes. Genes Dev. 10:1996;553-565.
156. Nacht M., Strasser A., Chan R.Y., Harris A.W., Schlissel M., Bronson T.R., Jacks T. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev. 10:1996;2055-2066.
157. Guidos J.C., Williams J.C., Gradal I., Knowles G., Huang T.F.M., Danska S.J. V(D)J recombination activates a p53-dependent DNA damage checkpoint in SCID lymphocyte precursors. Genes Dev. 10:1996;2038-2054.
158. Huang L., Clarkin C.K., Wahl M.G. p53-dependent cell cycle arrests are preserved in DNA-activated protein kinase-deficient mouse fibroblasts. Cancer Research. 56:1996;2940-2944.
159. Sturzbecher H.-W., Donzelmann B., Henning W., Knippschild U., Buchhop S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 15:1996;1992-2002.
160. Wiesmuller L., Cammenga J., Deppert W.W. In vivo assay of p53 function in homologous recombination between simian virus 40 chromosomes. J. Virol. 70:1996;737-744.
161. Lim D., Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol. cell. biol. 16:1996;7133-7143.
162. Cui W., Kemp C.J., Duffie E., Balmain A., Akhurst R.J. Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53 null mice is prognostic for a high risk of malignant conversion. Canc. Res. 54:1994;5831-5836.
163. Weintraub H., Hauschka S., Tapscott S.J. The MCK Enhancer Contains a p53 Responsive Elements. Proc. Natl. Acad. Sci. USA. 88:1991;4570-4571.
164. Hunter T. Braking the cycle. Cell. 75:1993;839-841.
165. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
166. 1 cyclin-dependent kinases. Cell. 75:1993;805-816.
167. Yang Z.-Y., Perkins N.D., Ohno T., Nabel E.G., Nabel G.J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigencity in vivo. Nat. Med. 1:1995;1052-1056.
168. Jiang H., Lin J., Su Z., Herlyn M., Kerbel S.R., Weissman E.B., Wech R.D., Fisher B.P. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene. 10:1995;1855-1864.
169. Jiag H., Lin J., Su Z.Z., Collart F.R., Huberman E., Fisher P.B. Induction of differentiation in human promyyelocytic HL-60 leukemia cells activates p21 WAF1/CIP1, expression in the absence of p53. Oncogene. 9:1994;3397-3406.
170. Steinman A.R., Hoffman B., Iro A., Guillouf C., Liebermann A.D., El-Houseini E.M. Induction of p21(WAF-1/CIP1) during differentiation. Oncogene. 9:1994;3389-3396.
171. Zhang W., Grasso L., McClain C.D., Gambel A.M., Cha Y., Travali S., Deisseroth A.B., Mercer W.E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Canc. Res. 55:1995;668-674.
172. Liu M., Lee M.H., Cohen M., Bommakanti M., Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10:1996;142-153.
173. Missero C., Calautti E., Ecker R., Chin J., Tsai L.H., Livingston D.M., Dotto G.P. Involvement of the cell cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protien in terminal differentiation. Proc. Natl. Acad. Sci. USA. 92:1995;5451-5455.
174. cip in muscle and other terminally differentiating cells. Science. 267:1995;1024-1027.
175. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Gene Develop. 9:1995;935-944.
176. Halevy O., Novitch B.G., Spicer D.B., Skapek S.X., Rhee J., Hannon G.J., Beach D., Lassar A.B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 of MyoD. Science. 267:1995;1018-1021.
177. Skapek, S.X., Rhee, J., Spicer, D.B. and Lassar, B. (1995) Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267, 1022.
178. CIP/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
179. Brugarolas J., Chandrasekaran C., Gordon I.J., Beach D., Jacks T., Hannon J.G. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:1995;552-557.
180. Soddu S., Blandino G., Scardigli R., Martinelli R., Rizzo G.M., Crescenzi M., Sacchi A. Wild type p53 induces diverse effects in 32D cells expressing different oncogenes. Mol. Cell Biol. 16:1996;487-495.
181. Reisman D., Rotter V. Two promoters that map to 5′-sequences of the human p53 gene are differentially regulated during terminal differentiation of human leukemic cells. Oncogene. 4:1989;945-953.
182. Khockbin S., Lawrence J.-J. An antisense RNA involved in p53 mRNA maturation in murine erythroleukemia cells induced to differentiate. EMBO J. 8(13):1989;4107-4114.
183. Shaulsky G., Goldfinger N., Tosky M.S., Levine A.J., Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene. 6:1991;2055-2065.
184. Moll U., LaQuaglia M., Benard J., Rious G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA. 92:1995;4407-4411.
185. Abrahamson J.L., Lee J.M., Bernstein A. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. Mol. cell Biol. 15:1995;6953-6960.
186. Chen X., Ko L.J., Jayaraman L., Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10:1996;2438-2451.
187. Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370:1994;220-223.
188. Haupt Y., Rowan S., Shaulian E., Vousden K.H., Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9:1995;2170-2183.
189. Avalosse B., Dupont F., Burny A. Gene theraphy for cancer. Curr. Opin. Oncol. 7:1995;94-100.
190. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
191. Petty D.R., Cree A.I., Sutherland A.L., Hunter M.E., Lane P.D., Preece E.P., Andreotti E.P. Expression of the p53 tumour suppressor gene product ia a determinant of chemosensitivity. Biochem. Biophys. Res. Commun. 199:1994;264-270.
192. Roth J.A., Nguyen O., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., Hong W.K., Komaki R., Lee J.J., Nesbitt J.C., Pisters K.M.W., Putnam J.B., Schea R., Shin D.M., Walsh G.L., Dolormente M.M., Han C.-I., Martin F.D., Yen N., Xu K., Stephens L.C., McDonnell T.J., Mukhopadhyay T., Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2:1996;985-991.
193. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
194. Sachs L. Contol of normal cell differnetiation and the phenotypic reversion of malignancy in myeloid leukemia. Nature. 274:1978;535-539.
195. Jimenez J.J., Yunis A.A. Tumor cell rejection through terminal cell differentiation. Science. 238:1987;1278-1280.
196. Jiang H., Lin J., Fisher B.P. A molecular definition of terminal cell differentiation in human melanoma cells. Mol. Cell. Diff. 2:1994;221-239.
197. Reiss M., Gamba-Vitalo C., Sartorelli C.A. Induction of tumor cell differentiation as a therapeutic approach: Preclinical models for hematopoitic and solid neoplasms. Cancer Treat. Rep. 70:1986;201-218.
198. Tallman M.S. Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia. Leukemia. 10:1996;12-15.
199. Tallman M.S. Differentiating therapy in acute myeloid leukemia. Leukemia. 10:1996;33-38.
200. Olsson I., Bergh G., Ehinger M., Gullberg U. Cell differentiation in acute myeloid leukemia. Eur. J. Haematol. 57:1996;1-16.
201. Chen Z., Tong J.H., Dong S., Zhu J., Wang Z.Y., Chen S.J. Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Genes Chromosomes Cancer. 15:1996;147-156.
202. Shaw P., Bovey R., Tardy S., Sahli R., Sordat B., Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA. 89:1992;4495-4499.
203. Peled A., Zipori D., Rotter V. Coperation between p53-dependent and p53-independent apoptotic pathway of Myloid cells. Cancer Res. 56:1996;2148-2156.